INOZYME PHARMA, INC.

Analyst Reco. Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
4.68 ^USD	-0.43%		+0.21%	+9.86%

May. 16	Transcript : Inozyme Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM
May. 07	Inozyme Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jefferies Upgrades Inozyme Pharma to Buy From Hold, Adjusts Price Target to $6 From $4.50	23-03-23	MT
Wedbush Lowers Inozyme Pharma's Price Target to $15 From $20, Keeps Outperform Rating	22-11-11	MT
Wedbush Adjusts Inozyme Pharma Price Target to $20 From $23, Maintains Outperform Rating	22-07-20	MT
Jefferies & Co. Initiates Inozyme Pharma, Inc at Hold, Price Target Set at $5	22-05-26	MT
HC Wainwright Lowers Inozyme Pharma's Price Target to $20 From $33, Maintains Buy Rating	22-05-11	MT
Wedbush Adjusts Price Target for Inozyme Pharma to $23 From $25, Maintains Outperform Rating	22-05-10	MT
Wedbush Adjusts Inozyme Pharma's Price Target to $25 From $35, Citing Cost of Capital; Outperform Rating Kept	22-03-16	MT
HC Wainwright Starts Inozyme Pharma at Buy With $33 Price Target	22-02-07	MT
Needham Starts Inozyme Pharma at Buy With $23 Price Target	21-11-29	MT
Wedbush Trims Inozyme Pharma's Price Target to $35 From $37; Outperform Rating Kept	21-11-10	MT
INOZYME PHARMA : Wedbush Adjusts Price Target on Inozyme Pharma to $37 From $35, Keeps Outperform Rating	20-11-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer